Is secukinumab effective for Chinese patients with psoriatic arthritis?
Secukinumab is a biologic drug that blocks interleukin-17, a protein involved in inflammation. For Chinese patients with psoriatic arthritis (PsA), studies show it works well to improve skin and joint symptoms. Real-world data from China and cost-effectiveness analyses support its use as a treatment option after other medications have failed.
What the research says
A 2020 real-world study in China looked at 81 patients with moderate-to-severe psoriasis, some of whom also had PsA. After 16 weeks of secukinumab treatment, 91.1% achieved at least a 75% improvement in skin symptoms (PASI 75), and quality of life improved significantly 9. However, the study noted that patients without PsA at baseline had better skin responses, suggesting that PsA may be a factor in treatment outcomes 9.
A 2025 network meta-analysis and cost-effectiveness study from the Chinese healthcare system evaluated seven biologics for active PsA after conventional treatments failed. Secukinumab had the highest quality-adjusted life years (QALYs) and was the most cost-effective option at a willingness-to-pay threshold of US $38,161 per QALY, with an incremental cost-effectiveness ratio of $14,968 per QALY 10. This means secukinumab provides good value for money in China.
While these studies focus on Chinese patients, broader research on secukinumab in PsA populations supports its efficacy. A 2021 protocol for a systematic review notes that IL-17 inhibitors like secukinumab have clinically validated efficacy and safety for PsA, though their effect on atherosclerosis (a common comorbidity) remains under study 11. Additionally, a narrative review on biologics in psoriasis patients with renal concerns mentions that IL-17 inhibitors, including secukinumab, are part of the therapeutic landscape, though it does not provide specific data on Chinese patients 1.
What to ask your doctor
- Is secukinumab a good option for my psoriatic arthritis, given my skin symptoms and overall health?
- What are the possible side effects of secukinumab, and how are they managed?
- How does secukinumab compare with other biologics or treatments available in China for PsA?
- Will my insurance or the healthcare system cover the cost of secukinumab?
- How long does it typically take to see improvement with secukinumab, and how will we monitor my response?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.